Ligand Enters Commercial License and Supply Agreements for Captisol®-enabled trametinib December 22, 2016
Ligand Enters into Worldwide OmniAb® Platform License Agreement with ONO PHARMACEUTICAL CO., LTD. December 22, 2016
Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 November 21, 2016
Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections October 24, 2016
Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference October 13, 2016
Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types October 7, 2016
Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis September 7, 2016
Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism August 15, 2016
Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals July 29, 2016